Investigational drug · Phase 3
HGP1201
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Erectile Dysfunction.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "HGP1201"
First trial start
2026
Oct 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HGP1201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Erectile Dysfunction
Approved drugs for the same conditions: Erectile dysfunction
Largest trials
Live from ClinicalTrials.gov: studies naming "HGP1201" as an intervention, largest first.
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 CapsulesPivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT02667938 · 510 participants · Start Mar 2015 · Primary completion Jan 2016
Drug: HCP1303 capsule 5/0.2mg; HCP1303 capsule 5/0.4mg and 4 more · For: Benign Prostatic Hyperplasia
- A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction PatientsPivotal-lookingRecruiting
Hanmi Pharmaceutical Company LimitedIndustry
NCT07899073 · 225 participants (planned) · Start Oct 2026 · Primary completion Sep 2027
Drug: HIP2602 + HPP2602-2; HPP2602-1 + HPP2602-2 and 1 more · For: Erectile Dysfunction
Sites: Busan, South Korea
Hanmi Pharmaceutical Company LimitedIndustry
NCT02715401 · 36 participants · Start Oct 2015 · Primary completion Nov 2015
Drug: HCP1303; HGP1201 and 1 more · For: Erectile Dysfunction; Prostatic Hyperplasia
Hanmi Pharmaceutical Company LimitedIndustry
NCT02712411 · 30 participants · Start Jul 2015 · Primary completion Aug 2015
Drug: HCP1303; HGP1201 and 1 more · For: Erectile Dysfunction; Prostatic Hyperplasia
Sites: Seodaemun-Gu, South Korea
Hanmi Pharmaceutical Company LimitedIndustry
NCT02243319 · 24 participants · Start Sep 2014 · Primary completion Dec 2014
Drug: HGP1201; HGP0904 and 1 more · For: Healthy
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Erectile Dysfunction
- TestofenPhase 32 trials
RDC Clinical Pty Ltd · Long Covid19, Erectile Dysfunction
- DTT106Phase 31 trial
EMS · Prostatic Hyperplasia, Benign, Erectile Dysfunction
- HIP2602Phase 31 trial
Hanmi Pharmaceutical Company Limited · Erectile Dysfunction
- HPP2602-1Phase 31 trial
Hanmi Pharmaceutical Company Limited · Erectile Dysfunction
- HPP2602-2Phase 31 trial
Hanmi Pharmaceutical Company Limited · Erectile Dysfunction
- TPN171HSimmerafilPhase 31 trial
Vigonvita Life Sciences · Erectile Dysfunction
- LIB-01Phase 21 trial
Dicot AB · Erectile Dysfunction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.